These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28901501)

  • 1. mTOR inhibition reduces growth and adhesion of hepatocellular carcinoma cells in vitro.
    Engl T; Rutz J; Maxeiner S; Juengel E; Roos F; Khoder W; Bechstein WO; Nelson K; Tsaur I; Haferkamp A; Blaheta RA
    Mol Med Rep; 2017 Nov; 16(5):7064-7071. PubMed ID: 28901501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.
    Tsaur I; Makarević J; Juengel E; Gasser M; Waaga-Gasser AM; Kurosch M; Reiter M; Wedel S; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
    Br J Cancer; 2012 Aug; 107(5):847-55. PubMed ID: 22782340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
    Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
    Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
    Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.
    Juengel E; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Tsaur I; Nelson K; Bechstein WO; Haferkamp A; Blaheta RA
    Oncotarget; 2016 Dec; 7(51):85208-85219. PubMed ID: 27863441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK.
    Relja B; Meder F; Wang M; Blaheta R; Henrich D; Marzi I; Lehnert M
    Int J Oncol; 2011 Mar; 38(3):879-85. PubMed ID: 21206971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
    Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.
    Tsaur I; Hudak L; Makarević J; Juengel E; Mani J; Borgmann H; Gust KM; Schilling D; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Aug; 19(8):1795-804. PubMed ID: 25808196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells.
    Masumoto A; Arao S; Otsuki M
    Hepatology; 1999 Jan; 29(1):68-74. PubMed ID: 9862852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha6beta1 integrin expression in hepatocarcinoma cells: regulation and role in cell adhesion and migration.
    Nejjari M; Hafdi Z; Dumortier J; Bringuier AF; Feldmann G; Scoazec JY
    Int J Cancer; 1999 Nov; 83(4):518-25. PubMed ID: 10508489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Integrin alpha3beta1 mediates hepatocellular carcinoma cell adhesion and chemotaxis to type IV collagen].
    Fu BH; Wu ZZ; Qin J; Li P; Liu LP; Cai SX; Dong C
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):967-71. PubMed ID: 12899798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of integrin beta1 and its roles on adhesion between different cell cycle hepatocellular carcinoma cells (SMMC-7721) and human umbilical vein endothelial cells.
    Song G; Luo Q; Qin J; Wang B; Cai S
    Colloids Surf B Biointerfaces; 2004 Apr; 34(4):247-52. PubMed ID: 15261064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laminin deposition to type IV collagen enhances haptotaxis, chemokinesis, and adhesion of hepatoma cells through beta1-integrins.
    Torimura T; Ueno T; Kin M; Harad R; Nakamura T; Sakamoto M; Kumashiro R; Yano H; Kojiro M; Sata M
    J Hepatol; 2001 Aug; 35(2):245-53. PubMed ID: 11580147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.
    Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies.
    Navarro-Villarán E; Tinoco J; Jiménez G; Pereira S; Wang J; Aliseda S; Rodríguez-Hernández MA; González R; Marín-Gómez LM; Gómez-Bravo MA; Padillo FJ; Álamo-Martínez JM; Muntané J
    PLoS One; 2016; 11(8):e0160979. PubMed ID: 27518575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
    Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
    Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.